G1 THERAPEUTICS INC's ticker is GTHX and the CUSIP is 3621LQ109. A total of 115 filers reported holding G1 THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 1.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,969 | -90.0% | 10,395 | -81.5% | 0.00% | – |
| Q1 2023 | $150,187 | -79.1% | 56,040 | -57.6% | 0.00% | – |
| Q4 2022 | $717,434 | -29.6% | 132,124 | +61.9% | 0.00% | – |
| Q3 2022 | $1,019,000 | +786.1% | 81,628 | +251.2% | 0.00% | – |
| Q2 2022 | $115,000 | -84.5% | 23,245 | -76.2% | 0.00% | – |
| Q1 2022 | $741,000 | -19.3% | 97,635 | +8.7% | 0.00% | – |
| Q4 2021 | $918,000 | -55.2% | 89,857 | -41.2% | 0.00% | – |
| Q3 2021 | $2,049,000 | -49.8% | 152,737 | -17.9% | 0.00% | -100.0% |
| Q2 2021 | $4,082,000 | -43.1% | 186,051 | -37.7% | 0.00% | -75.0% |
| Q1 2021 | $7,180,000 | +225.3% | 298,451 | +143.2% | 0.00% | – |
| Q4 2020 | $2,207,000 | +471.8% | 122,695 | +268.2% | 0.00% | – |
| Q3 2020 | $386,000 | +22.5% | 33,326 | +140.7% | 0.00% | -100.0% |
| Q3 2019 | $315,000 | -57.9% | 13,847 | -3.2% | 0.00% | 0.0% |
| Q3 2018 | $748,000 | – | 14,312 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 98,482 | $1,631,000 | 0.60% |
| Opus Point Partners Management, LLC | 20,844 | $346,000 | 0.47% |
| HHLR ADVISORS, LTD. | 949,431 | $15,761,000 | 0.44% |
| Rhenman & Partners Asset Management AB | 212,169 | $3,522,000 | 0.41% |
| Virtus ETF Advisers LLC | 8,654 | $144,000 | 0.31% |
| BB BIOTECH AG | 671,925 | $11,154,000 | 0.28% |
| RA Capital Management | 363,051 | $6,027,000 | 0.26% |
| BDO Wealth Advisors, LLC | 35,234 | $585,000 | 0.17% |
| Birchview Capital, LP | 15,000 | $249,000 | 0.16% |
| SECOR Capital Advisors, LP | 37,205 | $618,000 | 0.13% |